Telomerase-specific virotherapy for human squamous cell carcinoma

Expert Opinion on Biological Therapy

Volumn 9, Issue 3, 2009, Pages 321-329

  Fujiwara, Toshiyoshi ^a,b  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adenovirus; GFP; hTERT; Imaging; SCCHN; Telomerase

Indexed keywords

CETUXIMAB; CG 7870; E1A PROTEIN; E1B PROTEIN; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; OBP 301; OBP 401; OBP 405; ONCOLYTIC ADENOVIRUS; TELOMELYSIN; TELOMELYSIN RGD; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESCAN; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VRX 011; ONCOLYTIC VIRUS; TELOMERASE; TERT PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PATIENT; CARCINOMA CELL; CELL LABELING; CLINICAL TRIAL; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DISEASE MODEL; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LYMPH NODE METASTASIS; MICROMETASTASIS; MOLECULAR IMAGING; MONOTHERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TARGET CELL DESTRUCTION; TONGUE CARCINOMA; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR XENOGRAFT; VIRUS REPLICATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PHYSIOLOGY;

ADENOVIRIDAE;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TELOMERASE;

EID: 65549095995     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802715731     Document Type: Review

References (73)

1. Kaplan JM. Adenovirus-based cancer gene therapy. Curr Gene Ther 2005;5:595-605 (Pubitemid 43009504)
2. Dalba C, Klatzmann D, Logg CR, Kasahara N. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther 2005;5:655-667 (Pubitemid 43009509)
3. Le BC, Douar AM. Gene therapy progress and prospects-vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 2006;13:805-813
4. Hu YC. Baculovirus vectors for gene therapy. Adv Virus Res 2006;68:287-320 (Pubitemid 44402214)
5. Berges BK, Wolfe JH, Fraser NW. Transduction of brain by herpes simplex virus vectors. Mol Ther 2007;15:20-29 (Pubitemid 46043645)
6. Philpott NJ, Thrasher AJ. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther 2007;18:483-489 (Pubitemid 47036043)
7. Yonemitsu Y, Kitson C, Ferrari S, et al. Effi cient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000;18:970-973 (Pubitemid 32977378)
8. Mizuguchi H, Kay MA. Effi cient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998;9:2577-2583 (Pubitemid 29004630)
9. Stone D, Lieber A. New serotypes of adenoviral vectors. Curr Opin Mol Ther 2006;8:423-431 (Pubitemid 44566783)
10. Wilson JM, Engelhardt JF, Grossman M, et al. Gene therapy of cystic fi brosis lung disease using E1 deleted adenoviruses: a Phase I trial. Hum Gene Ther 1994;5:501-519 (Pubitemid 24304749)
11. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fi brosis. Nat Genet 1994;8:42-51 (Pubitemid 2122259)
12. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication defi cient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997;8:985-1001 (Pubitemid 27270161)
13. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-1092 (Pubitemid 28236516)
14. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-2291 (Pubitemid 24138709)
15. Fujiwara T, Cai DW, Georges RN, et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994;86:1458-1462 (Pubitemid 24317587)
16. Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 2000;60:1157-1161 (Pubitemid 30151973)
17. Tsunemitsu Y, Kagawa S, Tokunaga N, et al. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 2004;53:554-560 (Pubitemid 38372981)
18. Chen SH, Shine HD, Goodman JC, et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994;91:3054-3057 (Pubitemid 24130173)
19. Feldman AL, Restifo NP, Alexander HR, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000;60:1503-1506 (Pubitemid 30183414)
20. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-2232 (Pubitemid 28265061)
21. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-771 (Pubitemid 29239055)
22. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-622 (Pubitemid 30078542)
23. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003;9:93-101 (Pubitemid 36109720)
24. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter Phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24:1689-1699 (Pubitemid 46622140)
25. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol 2002;3:17-26 (Pubitemid 34121142)
26. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-defi cient human tumor cells. Science 1996;274:373-376 (Pubitemid 26353341)
27. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fl uorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-885 (Pubitemid 30644745)
28. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-298 (Pubitemid 32112839)
29. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-9490 (Pubitemid 28520811)
30. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995;269:1236-1241
31. Harrington L, McPhail T, Mar V, et al. A mammalian telomerase-associated protein. Science 1997;275:973-977 (Pubitemid 27087712)
32. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-795 (Pubitemid 27357969)
33. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959 (Pubitemid 27366681)
34. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fi broblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68 (Pubitemid 28027882)
35. Beattie TL, Zhou W, Robinson MO, Harrington L. Reconstitution of human telomerase activity in vitro. Curr Biol 1998;8:177-180 (Pubitemid 28091578)
36. Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identifi cation of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999;59:551-557 • The hTERT promoter was cloned and characterized in this interesting paper. (Pubitemid 29076049)
37. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999;59:826-830 (Pubitemid 29086735)
38. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
39. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-194
40. Vokes EE, Crawford J, Bogart J, et al. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 2005;11:5045s-50s
41. Milas L, Mason KA, Liao Z, Ang KK. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003;25:152-167
42. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791 (Pubitemid 27239490)
43. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003;63:3181-3188 (Pubitemid 36735870)
44. Lanson NA Jr, Friedlander PL, Schwarzenberger P, et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 2003;63:7936-7941 (Pubitemid 37466730)
45. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004;11:174-185 (Pubitemid 38280520)
46. Kim E, Kim JH, Shin HY, et al. Ad-mTERT-Δ19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specifi c manner. Hum Gene Ther 2003;14:1415-1428 (Pubitemid 37268220)
47. Kuppuswamy M, Spencer JF, Doronin K, et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 2005;12:1608-1617 (Pubitemid 41670351)
48. Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specifi c adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428-6436 (Pubitemid 32783248)
49. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specifi c replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-292 • This paper reported the construction of telomerase-specific oncolytic adenovirus, Telomelysin. (Pubitemid 38114191)
50. Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modifi ed telomerase-specifi c replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005;24:3130-3140 (Pubitemid 40695082)
51. Hashimoto Y, Watanabe Y, Shirakiya Y, et al. Establishment of biological and pharmacokinetic assays of telomerase-specifi c replication-selective adenovirus. Cancer Sci 2008;99:385-390 (Pubitemid 351228496)
52. Fujiwara T, Tanaka N, Nemunaitis J, et al. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specifi c oncolytic virus, in patients with advanced solid cancer: Evaluation of biodistribution and immune response. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:3572
53. Fujiwara T, Urata Y, Tanaka N. Diagnostic and therapeutic application of telomerase-specifi c oncolytic adenoviral agents. Front Biosci 2008;13:1881-1886 (Pubitemid 351599740)
54. Fidler IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 1986;5:29-49
55. Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Rev 1990;9:149-165 (Pubitemid 20311831)
56. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-284 (Pubitemid 29210167)
57. Hoffman RM. The multiple uses of fl uorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806 • This interesting review described various molecular imaging strategies using green fluorescent protein (GFP). (Pubitemid 41400779)
58. Watanabe T, Hioki M, Fujiwara T, et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specifi c replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006;312:256-265 (Pubitemid 41814835)
59. Fujiwara T, Kagawa S, Kishimoto H, et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of chemovirotherapy. Int J Cancer 2006;119:432-440 (Pubitemid 43911910)
60. Tearney GJ, Brezinski ME, Bouma BE, et al. In vivo endoscopic optical biopsy with optical coherence tomography. Science 1997;276:2037-2039
61. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-2808 (Pubitemid 40525178)
62. Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005;16(Suppl 6):vi7-vi12
63. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specifi c replication-selective adenovirus. Nat Med 2006;12:1213-1219
64. DeWeese TL, van der PH, Li S, et al. A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-7472 (Pubitemid 32995035)
65. Small EJ, Carducci MA, Burke JM, et al. A Phase I trial of intravenous CG7870, a replication-selective, prostate-specifi c antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-117 (Pubitemid 43899483)
66. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130
67. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-1709 (Pubitemid 351671886)
68. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743-1752 (Pubitemid 41079815)
69. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644-2652 (Pubitemid 46628471)
70. Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008;112:2635-2645
71. Widakowich C, de Castro G Jr, de Azambuja E, et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-1455
72. Okada N, Tsukada Y, Nakagawa S, et al. Effi cient gene delivery into dendritic cells by fi ber-mutant adenovirus vectors. Biochem Biophys Res Commun 2001;282:173-179 (Pubitemid 32924361)
73. Endo Y, Sakai R, Ouchi M, et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008;27:2375-2381